HAS gave iptacopan an ASMR III rating but restricted it to second-line use, anemic patients with haemoglobin below 10 g/dL after at least six months of prior anti-C5 therapy, a materially narrower population than the US or UK approvals cover.
France's Commission de la Transparence rated iptacopan (Fabhalta) ASMR III, a moderate improvement, in its 5 December 2024 economic opinion. That rating came with a restriction the FDA and MHRA labels do not carry. HAS positions iptacopan as a second-line option only, for adult patients with persistent hemolytic anemia, haemoglobin below 10 g/dL, after at least six months on a C5 complement inhibitor. Ravulizumab (Ultomiris) holds the opposite position. Its SMR, actual medical benefit, is rated important, and HAS considers it a first-line medicine for PNH, citing its every-eight-week dosing advantage over eculizumab's every-two-week schedule. The comparator relationship is asymmetric: ravulizumab defends first place; iptacopan has to earn its way in from second line.
That asymmetry sets the CEPS price negotiation up differently for each drug. Iptacopan's published reimbursement price is €29,590.96 excluding tax per box of 56 tablets, negotiated against a target population the manufacturer itself estimated at only 270 patients nationally, a genuinely small commercial base for a specialty price point. Ravulizumab's published price runs €14,988.66 for the 1100mg vial and €4,087.82 for the 300mg vial, reflecting weight-based dosing across a first-line population that never had to argue its way past a prior-treatment gate. A pricing strategy built on the US or UK label alone would miss this. France's second-line restriction shrinks iptacopan's addressable population before a single euro of price negotiation happens.
France PNH treatment landscape — HAS position and CEPS pricing by agent
| Agent | HAS Position | ASMR / SMR | French Reimbursement Price |
|---|---|---|---|
| Ultomiris (ravulizumab) | First-line | SMR: Important | €14,988.66 (1100mg) / €4,087.82 (300mg) |
| Fabhalta (iptacopan) | Second-line only (Hb <10 g/dL, ≥6mo prior anti-C5) | ASMR III | €29,590.96 per box of 56 tablets |
Sources: HAS Commission de la Transparence, Avis économique FABHALTA (iptacopan), 5 décembre 2024; HAS Commission de la Transparence, ULTOMIRIS (ravulizumab); French public medicines database (base-donnees-publique.medicaments.gouv.fr).
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- HAS's 5 December 2024 economic opinion and its exact eligibility language
- the ASMR III rating and what it reflects
- how this compares to the broader US/UK positioning
Delivers
- The manufacturer's own population estimate versus the published €29,590.96 reimbursement price
- small-population specialty pricing dynamics under CEPS's ASMR-anchored negotiation
Delivers
- Ravulizumab's SMR important rating and first-line status
- the q8w vs q2w dosing advantage HAS cited
- the asymmetric comparator relationship this creates for iptacopan
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- What French epidemiology data exists for PNH, and how it compares to UK/German extrapolation practice
- Diagnostic pathway through French reference centres
- How SMR and ASMR ratings drive reimbursement eligibility and CEPS price negotiation
- Where iptacopan and ravulizumab sit on each scale
- Eculizumab, ravulizumab, and iptacopan positioning under the French framework
- The exact Hb<10g/dL plus six-month anti-C5 criteria
- How this narrows the addressable population versus the US/UK label
- Published reimbursement prices for both agents
- What a small target population means for price negotiation leverage
- French PNH reference centre network
- Prescribing posture under the first-line/second-line split
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (HAS, EMA, ANSM) and live CEPS pricing documentation, not secondary summaries. Findings are independently verified before inclusion.
PNH France CI sources: HAS Commission de la Transparence economic opinion for iptacopan (5 December 2024), HAS Commission de la Transparence documentation for ravulizumab, and the French public medicines database for reimbursement pricing.
- Iptacopan's ASMR III rating and second-line restriction verified against the live HAS Commission de la Transparence economic opinion
- Ravulizumab's SMR important rating and first-line status verified against HAS Commission de la Transparence documentation
- Published reimbursement prices for both agents verified against the French public medicines database
Frequently asked questions
Commission this brief
AXLRx PNH Disease Landscape is built for commercial, medical affairs, and market access teams that need a rigorous, evidence-based characterisation of the French PNH patient population and the HAS/CEPS access pathway. Custom brief in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.